Disruption of Bile Acid Metabolism in the Gut–Liver Axis Predisposes Mice to Inflammatory Bowel Disease

Documenti analoghi

• The Gut‒Liver Axis in Liver Disease: Molecular Mechanisms and Therapeutic Targets
  di: Zhiji Chen, et al.
  Pubblicazione: (2025)
• ATP11B Modulates Microglial Lipid Metabolism and Alleviates Alzheimer's Disease Pathology
  di: Yuchen Zhang, et al.
  Pubblicazione: (2025)
• Dysfunctional Lipid‐Induced Secretion of Glucagon‐Like Peptide‐2(GLP‐2), but Not of Incretins Glucagon‐Like Peptide‐1(GLP‐1)/Glucose‐Dependent Insulinotropic Polypeptide(GIP), Promotes Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Onset and Progression Through Gut Barrier Disruption and Endotoxemia
  di: Giovanni Musso, et al.
  Pubblicazione: (2026)
• Alcohol‐Related Liver Disease and Metabolic Dysfunction‐Associated Steatotic Liver Disease: Molecular Pathogenesis and Therapeutic Interventions
  di: Yupin Tan, et al.
  Pubblicazione: (2025)
• Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study
  di: Jing Zhao, et al.
  Pubblicazione: (2025)